Trials / Recruiting
RecruitingNCT06491225
Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma
A Phase I, Open Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients with Advanced Lung Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Multiple centers, open design aimed at evaluating the safety,efficacy and Production feasibility of Autologous Tumor-Infiltrating Lymphocyte (GTE-001 injection ) for treatment of patients with Advanced lung adenocarcinoma,And evaluate potential biomarkers related to GTE-001 activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GTE001 injection | GTE-001 injection to treat Advanced lung adenocarcinoma |
Timeline
- Start date
- 2024-07-18
- Primary completion
- 2027-07-18
- Completion
- 2027-07-18
- First posted
- 2024-07-09
- Last updated
- 2025-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06491225. Inclusion in this directory is not an endorsement.